Elsevier Science, Inc.

SHERPA: Unknown

People

  1. Palomba
    Palomba
  2. Abdel-Wahab
    Abdel-Wahab
  3. Kumar
    Kumar
  4. Noy
    Noy
  5. Perales
    Perales
  6. Roeker
    Roeker
  7. Zelenetz
    Zelenetz
  8. Chadha
    Chadha
  9. Dogan
    Dogan
  10. Flaherty
    Flaherty

Groups

  1. Center for Hematologic Malignancies (13)
  2. Department of Medicine (13)
  3. Executive Committee, Center for Hematologic Malignancies (13)
  4. Hematologic Malignancies, Division of (13)
  5. Lymphoma (13)
  6. Nursing (4)
  7. Adult Leukemia (3)
  8. Advanced Practice Providers (3)
  9. GSK Faculty (3)
  10. Survivorship Research (3)
Search Within
  1. "Lymphoma"
  2. "Executive Committee, Center for Hematologic Malignancies"
Formats
  1. Journal Article (11)
  2. Editorial (1)
  3. Meeting Abstract (1)
Groups
  1. Center for Hematologic Malignancies (13)
  2. Department of Medicine (13)
  3. Executive Committee, Center for Hematologic Malignancies (13)
  4. Hematologic Malignancies, Division of (13)
  5. Lymphoma (13)
  6. Nursing (4)

More Groups

People
  1. Anas Younes (11)
  2. Maria Palomba (4)
  3. Andrew Zelenetz (2)
  4. Anita Kumar (2)
  5. Anthony Mato (2)
  6. Ariela Noy (2)

More People

Years
  1. 2021 (4)
  2. 2019 (3)
  3. 2018 (1)
  4. 2017 (1)
  5. 2016 (2)
  6. 2015 (1)

More Years

Publications
  1. Lancet Oncology (4)
  2. The Lancet Haematology (4)
  3. Journal of Molecular Diagnostics (2)
  4. Lancet (1)
  5. Translational Oncology (1)
  6. Value in Health (1)

Results (13)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: A multicentre, single-arm, phase 2 trial
    Journal Article

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V. E.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Hamilton, A. M.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial
    Journal Article

    Straus, D. J.; Długosz-Danecka, M.; Connors, J. M.; Alekseev, S.; Illés, Á; Picardi, M.; Lech-Maranda, E.; Feldman, T.; Smolewski, P.; Savage, K. J.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): A phase 1/2 study
    Journal Article

    Mato, A. R.; Shah, N. N.; Jurczak, W.; Cheah, C. Y.; Pagel, J. M.; Woyach, J. A.; Fakhri, B.; Eyre, T. A.; Lamanna, N.; Patel, M. R.; more...
    Lancet (2021)

    Fulltext@MSK | Save
  • Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation
    Journal Article

    Hodkinson, B. P.; Schaffer, M.; Brody, J. D.; Jurczak, W.; Carpio, C.; Ben-Yehuda, D.; Avivi, I.; Forslund, A.; Özcan, M.; Alvarez, J.; more...
    Translational Oncology (2021)

    Fulltext@MSK | Save
  • Will GALEN become more RELEVANT?
    Editorial

    von Keudell, G.; Younes, A.
    The Lancet Haematology (2019)

    Fulltext@MSK | Save
  • Resource utilization within 30 days of car T cells for hematologic malignancies
    Meeting Abstract

    Shah, G.; Park, J.; Sauter, C.; Duck, E.; Halton, E.; Batlevi, C.; Palomba, M. L.; Younes, A.; Geyer, M.; Smith, E.; more...
    Value in Health (2019)

    Fulltext@MSK | Save
  • Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: A phase 1/2a study
    Journal Article

    Younes, A.; Brody, J.; Carpio, C.; Lopez-Guillermo, A.; Ben-Yehuda, D.; Ferhanoglu, B.; Nagler, A.; Ozcan, M.; Avivi, I.; Bosch, F.; more...
    The Lancet Haematology (2019)

    Fulltext@MSK | Save
  • Authors' reply
    Journal Article

    Li, M. M.; Datto, M.; Duncavage, E. J.; Kulkarni, S.; Lindeman, N. I.; Roy, S.; Tsimberidou, A. M.; Vnencak-Jones, C. L.; Wolff, D. J.; Younes, A.; more...
    Journal of Molecular Diagnostics (2018)

    Fulltext@MSK | Save
  • Standards and guidelines for the interpretation and reporting of sequence variants in cancer: A joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists
    Journal Article

    Li, M. M.; Datto, M.; Duncavage, E. J.; Kulkarni, S.; Lindeman, N. I.; Roy, S.; Tsimberidou, A. M.; Vnencak-Jones, C. L.; Wolff, D. J.; Younes, A.; more...
    Journal of Molecular Diagnostics (2017)

    Fulltext@MSK | Save
  • Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
    Journal Article

    Younes, A.; Santoro, A.; Shipp, M.; Zinzani, P. L.; Timmerman, J. M.; Ansell, S.; Armand, P.; Fanale, M.; Ratanatharathorn, V.; Kuruvilla, J.; more...
    Lancet Oncology (2016)

    Fulltext@MSK | Save